World-First Koala Chlamydia Vaccine Approved
Australia has officially approved the first-ever vaccine to protect koalas from chlamydia, a breakthrough that could change the future for one of the country’s most iconic—and endangered—wildlife species.
Developed at the University of the Sunshine Coast (UniSC) after more than a decade of research, the single-dose vaccine protects against infection, reduces disease severity, and even reverses symptoms in some cases. Unlike antibiotics, which can interfere with a koala’s ability to digest eucalyptus leaves and don’t prevent reinfection, the vaccine provides long-term protection without compromising survival.
Why It Matters
Chlamydia is a leading cause of infertility, blindness, and death in koalas, with infection rates reaching up to 70% in some populations. The disease is responsible for nearly half of all koala deaths across Australia, pushing colonies in South East Queensland and New South Wales toward local extinction.
The Science Behind the Shot
The vaccine, based on Chlamydia pecorum’s major outer membrane protein (MOMP), combines six components: three proteins to cover different strains of the bacteria and three parts of a specially designed adjuvant. The result is a single-dose vaccine—critical for wildlife care where repeat handling is difficult.
Large-scale field trials confirmed its safety and effectiveness, showing a 65% reduction in chlamydia-related deaths among wild koalas.
Global and Local Collaboration
The project was led by Professor Peter Timms and his team at UniSC’s Centre for Bioinnovation, with support from partners including Tréidlia Biovet, the University of Saskatchewan, Ceva Santé Animale, and funding from the Bill & Melinda Gates Foundation. Wildlife hospitals, conservation groups like Australia Zoo, and both federal and state governments also played key roles in bringing the vaccine from the lab to the field.
A Turning Point for Conservation
Federal Environment Minister Murray Watt called the vaccine a “remarkable feat” supported by the government’s $76 million Saving Koalas Fund. Queensland has also invested millions in habitat protection, research, and wildlife hospital expansion.
UniSC Vice-Chancellor Professor Helen Bartlett described the vaccine as “a game-changing product that promises to ensure a future for the species,” while conservationist Dr. Terri Irwin said it represents the vital intersection of science, compassion, and action.
With this approval, veterinarians and wildlife carers can now use the vaccine in hospitals, clinics, and field settings—offering hope that Australia’s beloved koalas will not only survive, but thrive.
